香港联交所最新资料显示，2月9日，Healthblooming Limited增持脑动极光-B（06681）120万股，每股作 价4.6927港元，总金额约为563.12万港元。增持后最新持股数目为8210.4万股，最新持股比例为6.04%。 责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 香港联交所最新资料显示，2月9日，Healthblooming Limited增持脑动极光-B（06681）120万股，每股作 价4.6927港元，总金额约为563.12万港元。增持后最新持股数目为8210.4万股，最新持股比例为6.04%。 ...

Group 1 - Healthblooming Limited increased its stake in Brainstorm Cell Therapeutics Inc. (06681) by acquiring 1.2 million shares at a price of HKD 4.6927 per share, totaling approximately HKD 5.6312 million [1] - Following this transaction, Healthblooming Limited's total shareholding in Brainstorm Cell Therapeutics Inc. reached 82.104 million shares, representing a 6.04% ownership stake [1] - The transaction involved other related parties, specifically Zhao Yujie [1]

本交易涉及其他关联方：赵宇杰。 智通财经APP获悉，香港联交所最新资料显示，2月9日，Healthblooming Limited增持脑动极光- B(06681)120万股，每股作价4.6927港元，总金额约为563.12万港元。增持后最新持股数目为8210.4万 股，最新持股比例为6.04%。 ...

时间会记住那些持续向前的人。 继第一季「致敬成长」系列视频之后，北极光创投与创业邦再度携手，推出第二季特别策划。我们 邀请 到 XSKY星辰天合与脑动极光-B(06681.HK) 两家优秀的创业企业走到 台前，分享成长历 程，探讨初心、理想、成长、认知、价值等话题。过程中，投资人既是见证者，也是亲历者与陪伴 者，亦将一同分享他们眼中的成长。 这不仅是一场关于创业的交流，更是对成长的真挚致敬。在这个特别时刻，让我们一同感受成长的 力量，携手创勇者迎接更多挑战。 一场持续十三年的"极夜行军"， 如果你也曾创业，如果你关心医疗与科技的未来， 如果你好奇——一家公司如何在绝望中找到那束"极光"—— 那么，这个故事值得你点开。 脑动极 光，也 曾经历过最艰难的时期，账上资金仅能勉强维持，一支三十余人的团队，在困境中坚 守着一个看似遥远的梦想。 五年后，它却在港交所敲钟，成为"数字疗法第一股"。 这中间究竟发生了什么？ 是运气，还是坚持？ 如何走过至暗时刻？ 数字疗法，听起来像游戏，却要治好阿尔茨海默病、抑郁症…… 它究竟是黑科技，还是另一个泡沫？ 北极光 x 创业邦"致敬成长"往期精彩视频 ⬇️ ⬇️点击观看 听CEO ...

Core Viewpoint - BrainCo (06681) has signed a strategic cooperation agreement with Kiang Wu Hospital in Macau to develop a comprehensive brain health service model focusing on cognitive impairment screening, assessment, training, and health management [1][4]. Group 1: Company Developments - BrainCo's stock price increased by 3.89%, reaching HKD 4.81, with a trading volume of HKD 71.89 million [1][4]. - The agreement with Kiang Wu Hospital aims to establish a long-term strategic partnership in Macau, creating a full-chain brain health service model that integrates hospitals, communities, and home care [1][4].

Core Viewpoint - The company, Brainstorm Aurora-B (06681), has seen its stock price increase by over 4%, currently trading at 4.83 HKD with a transaction volume of 48.71 million HKD, following the announcement of a strategic partnership with Macau Kiang Wu Hospital to enhance digital health services for cognitive disorders [1] Group 1 - The company’s subsidiary, Brainstorm Aurora Medical Technology (Macau) Limited, has signed a cooperation agreement with Macau Kiang Wu Hospital to provide digital AI technology services for brain health [1] - The partnership aims to establish a comprehensive health management model covering "hospital-community-home" for cognitive disorder screening, assessment, training, and management in the Macau region [1] - The board believes this collaboration sets a benchmark for the group and opens up the Greater Bay Area market, marking the first flagship project for the group’s digital therapy in the Hong Kong-Macau region [1] Group 2 - The collaboration enriches the company's ecosystem alliance with authoritative medical institutions, complementing a recent national-level project partnership with the National Rehabilitation Aids Research Center under the Ministry of Civil Affairs [1] - This initiative aims to promote the standardization and large-scale application of cognitive digital therapies [1]

Core Viewpoint - The company Brainstorm Aurora-B (06681) has signed a strategic cooperation agreement with the Macau Kiang Wu Hospital to establish a comprehensive brain health service model in the Macau region, focusing on digital screening, assessment, training, and health management for cognitive disorders [1] Group 1 - The company's stock rose by 4.32%, reaching HKD 4.83, with a trading volume of HKD 48.71 million [1] - The partnership with the influential private hospital in Macau is seen as a benchmark for the company, paving the way for future expansion in the Greater Bay Area [1] - This collaboration enhances the company's ecosystem alliance with authoritative medical institutions, complementing its recent national-level project cooperation with the National Rehabilitation Aids Research Center [1]

Group 1 - Healthblooming Limited increased its stake in Brainstorm Cell Therapeutics Inc. (06681) by acquiring 9.8 million shares at a price of HKD 4.0279 per share, totaling approximately HKD 39.4734 million [1] - Following the acquisition, Healthblooming Limited's total shareholding in Brainstorm Cell Therapeutics Inc. reached 68.904 million shares, representing a 5.44% ownership stake [1] - The transaction involved other related parties, specifically Zhao Yujie [1]

Group 1 - Healthblooming Limited increased its stake in Brainstorm Cell Therapeutics Inc. (06681) by acquiring 9.8 million shares at a price of HKD 4.0279 per share, totaling approximately HKD 39.4734 million [1] - Following this transaction, Healthblooming Limited's total shareholding in Brainstorm Cell Therapeutics Inc. is now 68.904 million shares, representing a 5.44% ownership stake [1] - The transaction involves other related parties, specifically Zhao Yujie [1]

（文章来源：每日经济新闻） 每经AI快讯，2月9日，脑动极光-B(06681.HK)午前涨近5%，截至发稿涨3.96%，报4.73港元，成交额 5563.68万港元。 ...